查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1775570

醫療保健契約製造(CMO) 市場：2025-2030 年預測

Healthcare Contract Manufacturing Outsourcing (CMO) Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

醫療保健契約製造(CMO) 市場預計將從 2025 年的 2,006.27 億美元成長到 2030 年的 2,901.76 億美元，複合年成長率為 7.66%。

與其他產業一樣，醫療保健產業也在藥品和醫療設備的生產中利用外包流程。契約製造是將藥品和醫療設備的生產外包給專門從事此項業務的外包公司的做法。隨著患者數量的增加，醫院面臨維持充足設施的壓力，這些設施需要在基礎設施、人力、醫療照護、設備等方面滿足預期。與製藥和醫療設備製造商一樣，醫療保健產業也在尋求將部分流程外包，以便專注於核心競爭力，同時最大限度地降低營運成本。

醫療保健契約製造（CMO）市場趨勢：

醫療契約製造市場的經驗和專業知識正在推動需求。此外，醫療保健提供者可以避免不必要的資本支出，從而避免管理資源緊張。尋求進入醫療保健市場的新參與企業可以透過外包藥品和醫療設備的生產來生存，同時提供優質服務。成本因素是醫療合約製造市場蓬勃發展的主要原因。避免聘請專家並節省時間是該市場客戶獲得的額外好處。

醫療保健契約製造市場的成長動力：

  • 在預測期內，提高生產力並減少錯誤發生的可能性將有助於市場成長。

醫療保健行業的失誤可能會對患者造成致命打擊，並摧毀服務供應商辛苦賺來的收益。醫療保健CMO公司往往緊跟產業最新變化，並且能夠為客戶提供最佳解決方案。這推動了該行業公司的成長。藥物研發成本高昂，這也是醫療保健CMO產業蓬勃發展的主要原因之一。

此外，政府施壓要求在確保病患安全的同時保持競爭力和效率，這正在影響醫療保健產業的轉型方向。專利到期也是企業轉向醫療保健CMO的主要原因。規模經濟使CMO公司能夠最大限度地降低藥品生產成本並維持利潤，同時使醫療保健提供者能夠保留增量收益。

醫療保健契約製造市場的地理展望：

  • 由於已開發國家對醫療保健 CMO 公司的高度依賴，預計亞太地區在預測期內將出現高成長。

為了滿足日益成長的外科醫療設備和其他醫療輔助設備的需求，印度等國家正在將這些設備的製造外包，同時維持品質標準。美國等新興國家正大力投資更新和升級其生產設施，以提高生產效率。由於擁有大量製藥公司，美國佔據了相當大的市場派餅。由於政府的大力支持和生物製藥行業的蓬勃發展，歐洲地區也佔據了相當大的市場佔有率。

醫療保健契約製造市場產品供應

  • Lonza cGMP 製造：三大洲的 cGMP 製造能力涵蓋自體和同種異體細胞療法以及基於病毒載體的基因療法，使我們能夠支持處於臨床開發各個階段的新型療法的商業化。
  • AGC Biologics (AGC Inc) 配方開發：AGC Biologics 開發冷凍乾燥、液體和藥物產品配方，包括最佳化的冷凍乾燥週期。我們運用實驗設計 (DOE) 原則，進行廣泛且快速的輔料篩檢實驗，以盡可能辨識出能夠提高產品穩定性的輔料和條件。我們透過即時快速的穩定性測試，精心組合各種輔料和條件，以生產出理想的配方。我們生產的配方劑量濃度從微克到 175 mg/mL 以上。

醫療保健契約製造市場公司：

  • Pfizer Inc.
  • Lonza Group
  • AGC Biologics（AGC Inc）
  • Recipharm AB
  • Catalent, Inc.（Novo Holding A/S）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 經營狀況

  • 市場促進因素
  • 市場限制
  • 市場機會
  • 波特五力分析
  • 產業價值鏈分析
  • 政策法規
  • 策略建議

第4章 技術展望

5. 醫療保健契約製造（CMO）市場（按服務）

  • 介紹
  • 製藥CMO
    • 活性藥物成分 (API) 製造
    • 最終劑量配方（FDF）製造
      • 注射劑型
      • 固態劑型
      • 半固態製劑
      • 液體製劑
    • 包裹
  • 醫療設備CMO
    • 設計外包
    • 設備製造
    • 最終組裝

6. 醫療保健契約製造（CMO）市場（按產品類型）

  • 介紹
  • 已滅菌
  • 非無菌

7. 醫療保健契約製造（CMO）市場（按最終用戶）

  • 介紹
  • 製藥公司
  • 醫療設備公司
  • 其他

8. 醫療保健契約製造（CMO）市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 其他
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 印尼
    • 泰國
    • 其他

第9章：競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章：公司簡介

  • Jubilant Pharma Limited
  • Pfizer Inc.
  • Lonza Group AG
  • AGC Biologics（AGC Inc）
  • Recipharm AB
  • Catelent Inc（Novo Holding A/S）
  • Aenova Group
  • Boehringer Ingelheim International GmbH
  • AbbVie Inc
  • Fresenius Kabi AG

第11章 附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061610053

The Healthcare Contract Manufacturing Outsourcing (CMO) Market is expected to grow from US$200.627 billion in 2025 to US$290.176 billion in 2030, at a CAGR of 7.66%.

Like every other business, the Healthcare Sector also leverages the outsourcing process in the manufacture of drugs or medical devices. Contract manufacturing is a method for getting drugs and devices manufactured by an outsourcing firm specializing in that business. The increasing number of patients puts pressure on hospitals to maintain appropriate facilities to meet expectations in terms of infrastructure, workforce, medicine, and equipment. Outsourcing of some of the processes, like drug or medical device manufacturers, is being demanded by the healthcare sector to be able to focus on core competencies while minimizing the cost of operations.

Healthcare Contract Manufacturing Outsourcing (CMO) Market Trends:

Experience and expertise in the Healthcare outsourcing manufacturing market are driving the demand for such a market. On top of that, healthcare providers can avoid unnecessary capital investments, which might strain their resources. New players, willing to enter the healthcare market, can outsource the manufacture of drugs and devices to sustain their existence while providing quality services. The cost factor is the major reason for the booming Healthcare CMO market. Bypassing the process of hiring experts and saving time is an added advantage for the customers of this market.

Healthcare Contract Manufacturing Outsourcing Market Growth Drivers:

  • The increased productivity while reducing the probability of errors is contributing to the market growth in the forecast period.

Mistakes in the healthcare sector can be fatal for the patient and destroy the hard-earned earnings of the service provider. Healthcare CMO companies tend to remain up-to-date with the latest changes in the industry and can provide optimal solutions to their customers. This adds to the growth of the companies in this sector. Drug R&D is an expensive endeavor, which is one of the primary reasons why the Healthcare CMO Industry is thriving.

Besides, governmental pressure to remain competitive and efficient while ensuring the safety of patients is shaping the way the healthcare sector is transforming. Patent expiration is also a major reason why companies are resorting to a healthcare CMO. Due to economies of scale, CMO companies are able to minimize the cost of drug production and can maintain their profits while letting the healthcare service provider maintain their incremental profit.

Healthcare Contract Manufacturing Outsourcing Market Geographical Outlook:

  • The Asia Pacific region is expected to show higher growth prospects in the forecast period due to high dependence on healthcare CMO firms from developed countries.

To meet the rising demand for medical equipment for surgeries and other medical aids, countries, such as India, are outsourcing the manufacture of these devices while maintaining their quality standards. Developed countries, such as America, have significantly invested in updating and upgrading their facilities and enhancing production more efficiently. America shares a substantial portion of the pie of this market due to the presence of a large number of pharmaceutical companies. The European region also holds a major portion of the market due to high governmental support and the booming biopharmaceutical sector.

Healthcare Contract Manufacturing Outsourcing Market Product Offerings:

  • Lonza cGMP Manufacturing: Autologous and allogeneic cell treatments, as well as viral vector gene therapy, are all covered by cGMP manufacturing capabilities, which span three continents. It can aid in the commercialization of novel treatments at various phases of their clinical development. The NPI program uses experience and decades of expertise in building cGMP manufacturing standards, combining corporate and local quality standards, tailored for cell and gene therapies, to reduce the risk associated with clients' path to commercialization.
  • AGC Biologics (AGC Inc) formulation development: AGC Biologics creates formulations for lyophilized drug products, liquid drug substances, and drug products (together with optimized lyophilization cycles). Utilizing Design of Experiment (DOE) principles, they create extensive, quick excipient screening experiments to find excipients and circumstances that promote the greatest possible product stability. To produce an ideal formulation, they carefully examine various excipients and circumstances in combination using real-time and expedited stability studies. Formulations are created at dosage concentrations ranging from micrograms to >175 mg/mL.

Healthcare Contract Manufacturing Outsourcing Market Companies:

  • Pfizer Inc.
  • Lonza Group
  • AGC Biologics (AGC Inc)
  • Recipharm AB
  • Catalent, Inc. (Novo Holding A/S)

Healthcare Contract Manufacturing Outsourcing (CMO) Market Segmentation

By Service

  • Pharmaceutical CMO
  • Active Pharmaceutical Ingredients (API) Manufacturing
  • Final Dose Formulation (FDF) Mnuafacturing
  • Packaging
  • Medical Device (CMO)
  • Design Outsourcing
  • Device Manufacturing
  • Final Goods Assembly

By Product Type

  • Sterile
  • Non-Sterile

By End-User

  • Pharmaceutical Companies
  • Medical Device Companies
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indoensia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. HEALTHCARE CONTRACT MANUFACTURING OUTSOURCING (CMO) MARKET BY SERVICE

  • 5.1. Introduction
  • 5.2. Pharmaceutiucal CMO
    • 5.2.1. Active Pharmaceutical Ingredients (API) Manufacturing
    • 5.2.2. Final Dose Formulation (FDF) Mnuafacturing
      • 5.2.2.1. Injectable Dose Formulation
      • 5.2.2.2. Solid Dose Formulation
      • 5.2.2.3. Semi-Solid Formulation
      • 5.2.2.4. Liquid Dose Formulation
    • 5.2.3. Packaging
  • 5.3. Medical Device CMO
    • 5.3.1. Design Outsourcing
    • 5.3.2. Device Manufacturing
    • 5.3.3. Final Good Assembly

6. HEALTHCARE CONTRACT MANUFACTURING OUTSOURCING (CMO) MARKET BY PRODUCT TYPE

  • 6.1. Introduction
  • 6.2. Sterilized
  • 6.3. Non-Sterilized

7. HEALTHCARE CONTRACT MANUFACTURING OUTSOURCING (CMO) MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharamceutcial Companies
  • 7.3. Medical Device Companies
  • 7.4. Others

8. HEALTHCARE CONTRACT MANUFACTURING OUTSOURCING (CMO)MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Jubilant Pharma Limited
  • 10.2. Pfizer Inc.
  • 10.3. Lonza Group AG
  • 10.4. AGC Biologics (AGC Inc)
  • 10.5. Recipharm AB
  • 10.6. Catelent Inc (Novo Holding A/S)
  • 10.7. Aenova Group
  • 10.8. Boehringer Ingelheim International GmbH
  • 10.9. AbbVie Inc
  • 10.10. Fresenius Kabi AG

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations